Trial | NCT00756743  Report issue

Title

Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers
A Phase I Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04802540 After Multiple Oral Dose Administration To Healthy Adult Volunteers

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    pf-04802540 ...

  • Study Participants

    40
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to healthy adult subjects.
Evaluation of safety and pharmacokinetics
Study Started
Sep 30
2008
Primary Completion
Jan 31
2009
Study Completion
Jan 31
2009
Last Update
Mar 19
2010
Estimate

Drug PF-04802540

Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data

Drug Placebo

Placebo capsules q12 hours for 10 days

PF-04802540 Experimental

Placebo Placebo Comparator

Criteria 

Inclusion Criteria:

Males or females of non-childbearing capacity aged 21 to 55 years inclusive at screening.
Body mass index in the range of 18 to 30 kg/m2 and body weight>45 kg.
Healthy as determined by the investigator on the basis of screening evaluation.

Exclusion Criteria:

Use of prescription or nonprescription drugs
Any condition possibly affecting drug absorption
No Results Posted